As proposed by Dohner et al. (2024b), a four-gene model (TP53, FLT3-ITD, NRAS, KRAS) demonstrates superior predictive accuracy for elderly AML patients receiving non-intensive therapy. The gene discussed is TP53; the disease is acute myeloid leukemia.